Lupin 2023

NIH

NIH issues statement on Dr. Fauci leaving post in December

NIH issues statement on Dr. Fauci leaving post in December

BETHESDA, Md. — Dr. Anthony Fauci announced on Monday he plans to step down in December from his role as director of the National Institute of Allergy and Infectious Diseases—a position he held for more than 35 years, through the AIDS and COVID pandemics—as well as his role of chief medical adviser to President Joe

NIH releases faster, more user-friendly dietary supplement label database

NIH releases faster, more user-friendly dietary supplement label database

ROCKVILLE, Md.  –  The National Institutes of Health’s (NIH) Dietary Supplement Label Database (DSLD) has been redesigned and modernized, making it easier for users to learn about and search for dietary supplement products sold in the United States. The DSLD captures all the information printed on nearly 130,000 labels of dietary supplements and is regularly updated to

15 Nobel Laureates, other prominent figures urge Dr. Collins of NIH to prepare human challenge trials

15 Nobel Laureates, other prominent figures urge Dr. Collins of NIH to prepare human challenge trials

NEW YORK — In an open letter to Dr. Francis Collins, director of the National Institutes of Health (NIH), 15 Nobel Laureates are joined by over one hundred prominent figures and over two thousand 1Day Sooner challenge volunteers in advocating for the potential of challenge trials to accelerate COVID-19 vaccine development. The signatories come from a

NIH launches new platform to harness COVID-19 patient data

NIH launches new platform to harness COVID-19 patient data

WASHINGTON — The National Institutes of Health has launched a centralized, secure enclave to store and study vast amounts of medical record data from people diagnosed with coronavirus disease across the country. It is part of an effort, called the National COVID Cohort Collaborative (N3C) https://ncats.nih.gov/n3c/about, to help scientists analyze these data to understand the disease

NIH and FDA announcements confirm Agilum’s April 7th Real-World Evidence (RWE) of COVID-19 drug treatment observations

NIH and FDA announcements confirm Agilum’s April 7th Real-World Evidence (RWE) of COVID-19 drug treatment observations

DEERFIELD BEACH, Fla. —  The National Institutes of Health (NIH) released a statement this week warning against the use of hydroxychloroquine (HCQ) in combination with azithromycin. This conclusion mirrors Agilum Healthcare Intelligence’s real-world evidence published two weeks earlier on April 7th. Agilum was also pleased that the U.S. Food and Drug Administration (FDA) issued a

NIH clinical trial to evaluate the safety and effectiveness of hydroxychloroquine begins

NIH clinical trial to evaluate the safety and effectiveness of hydroxychloroquine begins

NEW YORK — A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has begun, with the first participants now enrolled in Tennessee. The Outcomes Related to COVID-19 treated with hydroxychloroquine among In-patients with symptomatic Disease study, or ORCHID Study, is being conducted

PP_1170x120_10-25-21